Aggressive variants of prostate cancer — Are we ready to apply specific treatment right now? Aggressive cancer in prostate, New urine test for prostate cancer Conținutul Abstract Recently, adoption of novel drugs for systemic treatment of metastatic prostate cancer has led to a striking improvement of response rate and survival in both hormone-sensitive and castration-resistant disease.
In most urine test prostate cancer, prostate cancer essentially depends on androgen receptor signaling axis, even in castration-resistant setting, and hence may be targeted by second generation hormonal therapy. However, a subset of patients bears androgen-independent cancer biology with a short-term response to urine test prostate cancer treatment, early and extensive visceral metastases, low PSA levels and poor outcomes.
Identification and specific management of these rapidly fatal malignancies is of an unmet medical need since their classification and utilized therapeutic regimens vary significantly. Magnetic Resonance Imaging MRI is the best imaging modality for evaluating the prostate and accurately diagnose the prostatic carcinoma, especially in cases with aggressive and larger volume tumors.
Hpv warts last Helminth therapy autism Unfortunately, molecular pathways have not been sufficiently elucidated yet in order to provide an effective targeted treatment with a prolonged response. Lack of diagnostic and predictive biomarkers for these cancers makes successful counteractions against them even more sophisticated.
In this comprehensive review, we aimed at summarizing the aggressive cancer in prostate body of literature reporting on causal molecular machinery as well as diagnostic and therapeutic concepts of aggressive prostate tumors and draw clinically relevant conclusions for the up-to-date sensible disease management.